| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 70 | 2024 | 2667 | 6.010 |
Why?
|
| Sarcoma | 31 | 2024 | 1839 | 3.200 |
Why?
|
| Osteosarcoma | 22 | 2020 | 948 | 2.440 |
Why?
|
| Femoral Neoplasms | 10 | 2018 | 66 | 2.410 |
Why?
|
| Hemipelvectomy | 7 | 2023 | 38 | 2.230 |
Why?
|
| Fractures, Spontaneous | 7 | 2018 | 87 | 1.920 |
Why?
|
| Soft Tissue Neoplasms | 15 | 2023 | 917 | 1.910 |
Why?
|
| Fracture Fixation, Intramedullary | 6 | 2024 | 41 | 1.850 |
Why?
|
| Femur | 10 | 2024 | 162 | 1.850 |
Why?
|
| Orthopedics | 5 | 2023 | 80 | 1.710 |
Why?
|
| Chondrosarcoma | 8 | 2023 | 213 | 1.640 |
Why?
|
| Limb Salvage | 11 | 2021 | 162 | 1.340 |
Why?
|
| Prosthesis Implantation | 6 | 2021 | 244 | 1.220 |
Why?
|
| Tibia | 6 | 2016 | 127 | 1.180 |
Why?
|
| Femoral Fractures | 4 | 2018 | 65 | 1.110 |
Why?
|
| Pelvic Bones | 8 | 2024 | 102 | 0.950 |
Why?
|
| Humerus | 5 | 2023 | 51 | 0.940 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 2 | 2017 | 14 | 0.920 |
Why?
|
| Lower Extremity | 8 | 2023 | 284 | 0.900 |
Why?
|
| Amputees | 1 | 2023 | 18 | 0.880 |
Why?
|
| Pelvic Neoplasms | 3 | 2024 | 203 | 0.880 |
Why?
|
| Bone Cysts, Aneurysmal | 3 | 2013 | 20 | 0.830 |
Why?
|
| Giant Cell Tumor of Bone | 7 | 2024 | 53 | 0.820 |
Why?
|
| Osteochondroma | 1 | 2021 | 11 | 0.780 |
Why?
|
| Neoplasm Recurrence, Local | 30 | 2023 | 10352 | 0.740 |
Why?
|
| Bone Transplantation | 11 | 2023 | 148 | 0.720 |
Why?
|
| Fibula | 7 | 2023 | 152 | 0.710 |
Why?
|
| Sarcoma, Ewing | 6 | 2019 | 426 | 0.710 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 213 | 0.710 |
Why?
|
| Retrospective Studies | 57 | 2023 | 39703 | 0.690 |
Why?
|
| Chronic Pain | 1 | 2023 | 262 | 0.670 |
Why?
|
| Leg Length Inequality | 3 | 2024 | 12 | 0.650 |
Why?
|
| Patella | 2 | 2016 | 39 | 0.650 |
Why?
|
| Frozen Sections | 1 | 2019 | 118 | 0.640 |
Why?
|
| Chondrosarcoma, Mesenchymal | 2 | 2018 | 16 | 0.620 |
Why?
|
| Bone Diseases | 1 | 2019 | 142 | 0.610 |
Why?
|
| Humans | 132 | 2024 | 270832 | 0.610 |
Why?
|
| Bone and Bones | 3 | 2023 | 612 | 0.590 |
Why?
|
| Orthopedic Procedures | 10 | 2019 | 144 | 0.590 |
Why?
|
| Treatment Outcome | 53 | 2024 | 33837 | 0.570 |
Why?
|
| Arthralgia | 2 | 2015 | 97 | 0.560 |
Why?
|
| Hip Prosthesis | 3 | 2013 | 32 | 0.520 |
Why?
|
| Chondroma | 2 | 2013 | 30 | 0.520 |
Why?
|
| Free Tissue Flaps | 5 | 2022 | 374 | 0.510 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 533 | 0.510 |
Why?
|
| Male | 79 | 2024 | 128425 | 0.490 |
Why?
|
| Female | 84 | 2024 | 148552 | 0.490 |
Why?
|
| Femur Neck | 1 | 2014 | 21 | 0.490 |
Why?
|
| Adult | 65 | 2024 | 81579 | 0.490 |
Why?
|
| Upper Extremity | 2 | 2015 | 83 | 0.490 |
Why?
|
| Knee Joint | 2 | 2015 | 168 | 0.490 |
Why?
|
| Biopsy | 4 | 2019 | 3543 | 0.480 |
Why?
|
| Adolescent | 47 | 2023 | 32534 | 0.470 |
Why?
|
| Ifosfamide | 3 | 2015 | 357 | 0.470 |
Why?
|
| Receptors, Interleukin-11 | 1 | 2014 | 9 | 0.470 |
Why?
|
| Cancer Pain | 1 | 2019 | 344 | 0.460 |
Why?
|
| Hip Dislocation | 1 | 2014 | 29 | 0.450 |
Why?
|
| Osteogenesis, Distraction | 2 | 2024 | 58 | 0.450 |
Why?
|
| Radiography | 13 | 2020 | 1991 | 0.440 |
Why?
|
| Middle Aged | 63 | 2024 | 90054 | 0.440 |
Why?
|
| Leg | 3 | 2011 | 216 | 0.440 |
Why?
|
| Cell Dedifferentiation | 1 | 2013 | 101 | 0.430 |
Why?
|
| Peptides, Cyclic | 1 | 2014 | 134 | 0.430 |
Why?
|
| Extremities | 5 | 2023 | 308 | 0.420 |
Why?
|
| Aged | 51 | 2024 | 73214 | 0.420 |
Why?
|
| Neurofibromatosis 1 | 1 | 2014 | 151 | 0.410 |
Why?
|
| Osteotomy | 5 | 2015 | 105 | 0.410 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2013 | 101 | 0.390 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2011 | 16 | 0.390 |
Why?
|
| Giant Cell Tumors | 1 | 2011 | 33 | 0.390 |
Why?
|
| Peptides | 1 | 2017 | 1525 | 0.380 |
Why?
|
| Cultural Diversity | 1 | 2012 | 80 | 0.380 |
Why?
|
| Muscle Neoplasms | 2 | 2009 | 108 | 0.380 |
Why?
|
| Reoperation | 11 | 2023 | 1389 | 0.380 |
Why?
|
| Arm | 2 | 2011 | 138 | 0.370 |
Why?
|
| Humeral Fractures | 1 | 2011 | 23 | 0.370 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2019 | 2266 | 0.370 |
Why?
|
| Child | 31 | 2023 | 30366 | 0.370 |
Why?
|
| Physicians, Women | 1 | 2012 | 99 | 0.360 |
Why?
|
| Plasminogen | 2 | 2001 | 28 | 0.360 |
Why?
|
| Young Adult | 22 | 2021 | 22052 | 0.360 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 157 | 0.350 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 609 | 0.350 |
Why?
|
| Sentinel Lymph Node | 2 | 2023 | 229 | 0.350 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2024 | 302 | 0.340 |
Why?
|
| Combined Modality Therapy | 17 | 2020 | 9041 | 0.340 |
Why?
|
| Radiosurgery | 1 | 2019 | 1368 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2019 | 6251 | 0.330 |
Why?
|
| Chordoma | 1 | 2011 | 170 | 0.330 |
Why?
|
| Liposarcoma | 2 | 2024 | 247 | 0.330 |
Why?
|
| Aged, 80 and over | 24 | 2023 | 30953 | 0.330 |
Why?
|
| Torso | 3 | 2020 | 72 | 0.320 |
Why?
|
| Postoperative Complications | 10 | 2021 | 5687 | 0.320 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 1019 | 0.320 |
Why?
|
| Clavicle | 1 | 2008 | 67 | 0.310 |
Why?
|
| Curettage | 3 | 2021 | 22 | 0.300 |
Why?
|
| Range of Motion, Articular | 5 | 2019 | 112 | 0.300 |
Why?
|
| Fibroma | 1 | 2008 | 87 | 0.290 |
Why?
|
| Knee | 1 | 2007 | 31 | 0.290 |
Why?
|
| Prognosis | 17 | 2021 | 22462 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 3 | 2019 | 357 | 0.290 |
Why?
|
| Argon | 1 | 2007 | 5 | 0.290 |
Why?
|
| Prostheses and Implants | 3 | 2021 | 296 | 0.290 |
Why?
|
| Disease-Free Survival | 15 | 2019 | 10249 | 0.290 |
Why?
|
| Medical Oncology | 2 | 2022 | 1462 | 0.290 |
Why?
|
| Diagnosis, Differential | 6 | 2014 | 4888 | 0.290 |
Why?
|
| Bone Nails | 3 | 2024 | 32 | 0.280 |
Why?
|
| Fibromatosis, Aggressive | 2 | 2020 | 110 | 0.280 |
Why?
|
| Kidney Neoplasms | 5 | 2024 | 3146 | 0.270 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 736 | 0.270 |
Why?
|
| Laser Coagulation | 1 | 2007 | 141 | 0.260 |
Why?
|
| Communication | 1 | 2012 | 854 | 0.260 |
Why?
|
| Fractures, Bone | 3 | 2023 | 312 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2024 | 2415 | 0.250 |
Why?
|
| Bone Cements | 2 | 2024 | 50 | 0.250 |
Why?
|
| Antineoplastic Agents | 6 | 2017 | 14651 | 0.250 |
Why?
|
| Bone Development | 1 | 2005 | 83 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2015 | 3972 | 0.250 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 15241 | 0.240 |
Why?
|
| Cryosurgery | 2 | 2017 | 186 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 2428 | 0.240 |
Why?
|
| Shoulder Joint | 2 | 2019 | 63 | 0.240 |
Why?
|
| Surgical Flaps | 2 | 2023 | 882 | 0.230 |
Why?
|
| Osteocytes | 1 | 2024 | 35 | 0.230 |
Why?
|
| Gap Junctions | 1 | 2024 | 50 | 0.230 |
Why?
|
| Prosthesis-Related Infections | 3 | 2021 | 229 | 0.230 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2006 | 401 | 0.230 |
Why?
|
| Orthopedic Surgeons | 1 | 2023 | 13 | 0.220 |
Why?
|
| Tendons | 2 | 2015 | 76 | 0.220 |
Why?
|
| Denosumab | 1 | 2024 | 72 | 0.220 |
Why?
|
| Diaphyses | 1 | 2023 | 11 | 0.220 |
Why?
|
| Survival Analysis | 13 | 2019 | 9304 | 0.220 |
Why?
|
| Muscles | 2 | 2023 | 461 | 0.220 |
Why?
|
| Perfectionism | 1 | 2023 | 2 | 0.220 |
Why?
|
| Psoas Muscles | 1 | 2023 | 12 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 6 | 2024 | 5206 | 0.220 |
Why?
|
| Time and Motion Studies | 1 | 2023 | 45 | 0.220 |
Why?
|
| Epithelioid Cells | 1 | 2003 | 43 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 4 | 2018 | 2397 | 0.210 |
Why?
|
| Peripheral Nerves | 1 | 2023 | 162 | 0.210 |
Why?
|
| Disease Progression | 8 | 2024 | 6895 | 0.210 |
Why?
|
| Time Factors | 11 | 2019 | 13107 | 0.210 |
Why?
|
| Spinal Neoplasms | 3 | 2024 | 664 | 0.210 |
Why?
|
| Neoplasm Staging | 13 | 2022 | 13979 | 0.210 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 479 | 0.210 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2024 | 299 | 0.200 |
Why?
|
| Lung Neoplasms | 7 | 2017 | 11774 | 0.200 |
Why?
|
| Osteolysis | 4 | 2024 | 99 | 0.200 |
Why?
|
| Postural Balance | 1 | 2023 | 141 | 0.190 |
Why?
|
| Venous Thrombosis | 2 | 2020 | 378 | 0.190 |
Why?
|
| Hemangioma | 1 | 2003 | 160 | 0.190 |
Why?
|
| Scapula | 2 | 2015 | 33 | 0.190 |
Why?
|
| Prosthesis Failure | 4 | 2019 | 201 | 0.190 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 958 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2021 | 7786 | 0.180 |
Why?
|
| Osteosarcoma, Juxtacortical | 1 | 2000 | 4 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2021 | 56 | 0.180 |
Why?
|
| Pain | 2 | 2016 | 1695 | 0.180 |
Why?
|
| Surgical Oncology | 1 | 2023 | 208 | 0.180 |
Why?
|
| Child, Preschool | 9 | 2020 | 16925 | 0.180 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2023 | 318 | 0.170 |
Why?
|
| Biological Products | 1 | 2024 | 316 | 0.170 |
Why?
|
| Chondroblastoma | 2 | 2013 | 16 | 0.170 |
Why?
|
| Neoplasms | 4 | 2022 | 15854 | 0.170 |
Why?
|
| Survival Rate | 14 | 2020 | 12516 | 0.170 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2019 | 18 | 0.170 |
Why?
|
| Osteoma, Osteoid | 2 | 2013 | 24 | 0.170 |
Why?
|
| Infant | 7 | 2020 | 13873 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 1 | 2019 | 7 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2015 | 7927 | 0.170 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 1177 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2019 | 259 | 0.160 |
Why?
|
| Drainage | 1 | 2021 | 448 | 0.160 |
Why?
|
| Thrombophlebitis | 1 | 2018 | 35 | 0.150 |
Why?
|
| Sarcoma, Synovial | 2 | 2010 | 130 | 0.150 |
Why?
|
| Clinical Protocols | 2 | 2018 | 485 | 0.150 |
Why?
|
| Hip Fractures | 1 | 2018 | 88 | 0.150 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 5087 | 0.150 |
Why?
|
| Lidocaine | 1 | 2017 | 79 | 0.150 |
Why?
|
| Autocrine Communication | 1 | 2017 | 93 | 0.140 |
Why?
|
| Surgeons | 1 | 2023 | 486 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 2 | 2024 | 1133 | 0.140 |
Why?
|
| Prosthesis Design | 2 | 2013 | 663 | 0.140 |
Why?
|
| Fracture Healing | 1 | 2016 | 43 | 0.140 |
Why?
|
| Career Choice | 2 | 2023 | 206 | 0.140 |
Why?
|
| Risk Factors | 10 | 2023 | 17819 | 0.140 |
Why?
|
| Lymphatic Metastasis | 4 | 2023 | 4967 | 0.140 |
Why?
|
| Cementation | 2 | 2024 | 10 | 0.130 |
Why?
|
| Epiphyses | 1 | 2015 | 14 | 0.130 |
Why?
|
| Radiation Injuries | 2 | 2022 | 1472 | 0.130 |
Why?
|
| Patellar Ligament | 1 | 2015 | 12 | 0.130 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2015 | 562 | 0.130 |
Why?
|
| Hand Bones | 1 | 2015 | 8 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 569 | 0.130 |
Why?
|
| Texas | 3 | 2020 | 6412 | 0.120 |
Why?
|
| Osteoblasts | 1 | 2017 | 394 | 0.120 |
Why?
|
| Risk Assessment | 7 | 2019 | 6831 | 0.120 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2015 | 65 | 0.120 |
Why?
|
| Foot Diseases | 1 | 2015 | 49 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 14854 | 0.120 |
Why?
|
| Multiple Trauma | 1 | 2015 | 76 | 0.120 |
Why?
|
| Lymphoma | 1 | 2003 | 1513 | 0.120 |
Why?
|
| Cell Engineering | 1 | 2014 | 35 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 4330 | 0.110 |
Why?
|
| Anesthesia, Conduction | 1 | 2014 | 44 | 0.110 |
Why?
|
| Peptide Library | 1 | 2014 | 165 | 0.110 |
Why?
|
| Ilium | 1 | 2013 | 54 | 0.110 |
Why?
|
| Analgesia | 1 | 2014 | 98 | 0.110 |
Why?
|
| Pain Management | 1 | 2019 | 715 | 0.110 |
Why?
|
| Organ Sparing Treatments | 1 | 2015 | 280 | 0.110 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2013 | 12 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 366 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 1458 | 0.110 |
Why?
|
| Recovery of Function | 3 | 2019 | 691 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 801 | 0.100 |
Why?
|
| Radiotherapy | 4 | 2008 | 1858 | 0.100 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4838 | 0.100 |
Why?
|
| Prejudice | 1 | 2012 | 52 | 0.100 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2011 | 19 | 0.100 |
Why?
|
| Synovial Membrane | 1 | 2011 | 47 | 0.100 |
Why?
|
| Leg Bones | 1 | 2011 | 10 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2019 | 8580 | 0.100 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2011 | 72 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2015 | 1066 | 0.090 |
Why?
|
| Cultural Competency | 1 | 2012 | 69 | 0.090 |
Why?
|
| Leadership | 2 | 2023 | 261 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2011 | 2118 | 0.090 |
Why?
|
| Tibial Fractures | 1 | 2011 | 63 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 5186 | 0.090 |
Why?
|
| Faculty, Medical | 2 | 2023 | 308 | 0.090 |
Why?
|
| Cohort Studies | 6 | 2023 | 9434 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2017 | 4356 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 604 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2015 | 1377 | 0.090 |
Why?
|
| Apoptosis | 1 | 2024 | 7828 | 0.090 |
Why?
|
| Gene Expression | 2 | 2017 | 3678 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 3171 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.080 |
Why?
|
| Disease Management | 1 | 2015 | 1111 | 0.080 |
Why?
|
| Imatinib Mesylate | 2 | 2011 | 1690 | 0.080 |
Why?
|
| Fracture Fixation, Internal | 1 | 2009 | 96 | 0.080 |
Why?
|
| Arthroplasty, Replacement | 1 | 2009 | 38 | 0.080 |
Why?
|
| Eosinophilic Granuloma | 1 | 2008 | 15 | 0.080 |
Why?
|
| Sternoclavicular Joint | 1 | 2008 | 6 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 16600 | 0.080 |
Why?
|
| Quality of Life | 2 | 2015 | 4740 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 657 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2015 | 1199 | 0.070 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2007 | 38 | 0.070 |
Why?
|
| Family | 1 | 2012 | 762 | 0.070 |
Why?
|
| Joint Instability | 1 | 2008 | 78 | 0.070 |
Why?
|
| Benzamides | 2 | 2011 | 1882 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2012 | 681 | 0.070 |
Why?
|
| Arthroplasty | 1 | 2007 | 22 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 338 | 0.070 |
Why?
|
| Pyrroles | 1 | 2011 | 592 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 1820 | 0.070 |
Why?
|
| Acetabulum | 1 | 2007 | 41 | 0.070 |
Why?
|
| Osteoradionecrosis | 1 | 2008 | 128 | 0.070 |
Why?
|
| Comorbidity | 2 | 2011 | 2434 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2009 | 312 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5325 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 1598 | 0.070 |
Why?
|
| Periosteum | 1 | 2007 | 41 | 0.070 |
Why?
|
| Radiotherapy Dosage | 3 | 2015 | 4003 | 0.070 |
Why?
|
| Animals | 7 | 2024 | 62749 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 915 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2337 | 0.070 |
Why?
|
| Forecasting | 1 | 2009 | 705 | 0.070 |
Why?
|
| Physical Examination | 1 | 2008 | 303 | 0.070 |
Why?
|
| Ligands | 1 | 2009 | 1057 | 0.070 |
Why?
|
| Algorithms | 2 | 2015 | 3904 | 0.070 |
Why?
|
| Indoles | 1 | 2011 | 1034 | 0.060 |
Why?
|
| United States | 4 | 2012 | 15994 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2023 | 1449 | 0.060 |
Why?
|
| Doxorubicin | 3 | 2015 | 3131 | 0.060 |
Why?
|
| Bone Screws | 1 | 2005 | 86 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 2023 | 2044 | 0.060 |
Why?
|
| Macrophages | 1 | 2011 | 1373 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2022 | 1038 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 4125 | 0.060 |
Why?
|
| Connexin 43 | 1 | 2024 | 46 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2001 | 1327 | 0.060 |
Why?
|
| Graft Survival | 1 | 2008 | 1093 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 3070 | 0.060 |
Why?
|
| Thoracic Neoplasms | 1 | 2007 | 347 | 0.060 |
Why?
|
| Piperazines | 2 | 2011 | 2151 | 0.060 |
Why?
|
| Catheter Ablation | 2 | 2010 | 575 | 0.060 |
Why?
|
| Neoplasm, Residual | 3 | 2015 | 1740 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 5156 | 0.060 |
Why?
|
| Wound Healing | 4 | 2012 | 758 | 0.060 |
Why?
|
| Bone Marrow Examination | 1 | 2003 | 151 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2005 | 135 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 1338 | 0.050 |
Why?
|
| Mice | 5 | 2024 | 35996 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2007 | 555 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 1259 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 126 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 271 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2024 | 201 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2015 | 2034 | 0.050 |
Why?
|
| Spinal Cord Compression | 1 | 2024 | 166 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 157 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 4069 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2024 | 205 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2023 | 3067 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 728 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 658 | 0.050 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2001 | 39 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2001 | 164 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 2286 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 565 | 0.050 |
Why?
|
| Fibrosarcoma | 1 | 2001 | 142 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 741 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5902 | 0.050 |
Why?
|
| Mentors | 1 | 2023 | 203 | 0.050 |
Why?
|
| Pyrimidines | 2 | 2011 | 3664 | 0.040 |
Why?
|
| Immunogenetic Phenomena | 1 | 2020 | 9 | 0.040 |
Why?
|
| Cell Division | 2 | 2002 | 2711 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2006 | 1550 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2014 | 3535 | 0.040 |
Why?
|
| Motivation | 1 | 2023 | 510 | 0.040 |
Why?
|
| Shoulder Prosthesis | 1 | 2019 | 3 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 715 | 0.040 |
Why?
|
| Circular Dichroism | 1 | 1999 | 107 | 0.040 |
Why?
|
| Factor Xa | 1 | 1999 | 24 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4495 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2023 | 520 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 5105 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 1999 | 163 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2007 | 1379 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 1999 | 341 | 0.040 |
Why?
|
| Edema | 1 | 2020 | 263 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2019 | 297 | 0.040 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 2198 | 0.040 |
Why?
|
| Bone Density | 1 | 2021 | 470 | 0.040 |
Why?
|
| Transplantation, Homologous | 3 | 2011 | 3033 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 360 | 0.040 |
Why?
|
| Protein Folding | 1 | 1999 | 299 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 1425 | 0.040 |
Why?
|
| Palliative Care | 1 | 2009 | 2156 | 0.040 |
Why?
|
| Veins | 1 | 2018 | 166 | 0.040 |
Why?
|
| Registries | 2 | 2015 | 2238 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 1323 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2014 | 12198 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 219 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 138 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 272 | 0.030 |
Why?
|
| Allografts | 1 | 2019 | 684 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 725 | 0.030 |
Why?
|
| Risk | 1 | 2021 | 1913 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2017 | 4190 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 10694 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 1458 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4386 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1999 | 609 | 0.030 |
Why?
|
| Evidence-Based Medicine | 3 | 2005 | 1057 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 378 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1401 | 0.030 |
Why?
|
| Hand Dermatoses | 1 | 2015 | 28 | 0.030 |
Why?
|
| Foot Dermatoses | 1 | 2015 | 25 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 745 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 726 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2015 | 291 | 0.030 |
Why?
|
| Radiodermatitis | 1 | 2015 | 79 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 553 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2001 | 1264 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1134 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2015 | 671 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1209 | 0.030 |
Why?
|
| Iliac Vein | 1 | 2013 | 41 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 261 | 0.030 |
Why?
|
| Femoral Vein | 1 | 2013 | 64 | 0.030 |
Why?
|
| Iliac Artery | 1 | 2013 | 100 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2817 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1999 | 1308 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 1728 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 4631 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 559 | 0.030 |
Why?
|
| Base Sequence | 1 | 1999 | 5484 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 878 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2015 | 890 | 0.020 |
Why?
|
| Patient Selection | 2 | 2010 | 2041 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 15850 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 371 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 6767 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 1092 | 0.020 |
Why?
|
| Yohimbine | 1 | 1991 | 32 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 2560 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 3653 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2015 | 688 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2014 | 494 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 3415 | 0.020 |
Why?
|
| Naloxone | 1 | 1991 | 109 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2011 | 185 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 7216 | 0.020 |
Why?
|
| Fracture Fixation | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2010 | 67 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2009 | 64 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3537 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2285 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1991 | 257 | 0.020 |
Why?
|
| Morphine | 1 | 1991 | 332 | 0.020 |
Why?
|
| Liver | 1 | 1999 | 3122 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1999 | 6478 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2009 | 13365 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 5838 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 7812 | 0.020 |
Why?
|
| Proteomics | 1 | 2015 | 1435 | 0.020 |
Why?
|
| Analgesics | 1 | 1991 | 409 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 876 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2007 | 143 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 988 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2010 | 508 | 0.020 |
Why?
|
| Foreign-Body Migration | 1 | 2007 | 121 | 0.020 |
Why?
|
| Joints | 1 | 2005 | 43 | 0.020 |
Why?
|
| Retreatment | 1 | 2007 | 447 | 0.020 |
Why?
|
| Radius | 1 | 2005 | 44 | 0.020 |
Why?
|
| Microsurgery | 1 | 2007 | 234 | 0.020 |
Why?
|
| Laminectomy | 1 | 2005 | 52 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 445 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7291 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 16188 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 1017 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7466 | 0.010 |
Why?
|
| Decompression, Surgical | 1 | 2005 | 147 | 0.010 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2004 | 19 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 1432 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 1567 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 1313 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 2315 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 604 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 109 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 431 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 449 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 2047 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 748 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2009 | 2285 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 1439 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 770 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2002 | 490 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2007 | 1005 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 5486 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 1565 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 1372 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 2496 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 5099 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 3644 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2002 | 2099 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 5802 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 1965 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 1842 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 4982 | 0.010 |
Why?
|
| Drug Implants | 1 | 1991 | 53 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 483 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4795 | 0.010 |
Why?
|
| Reaction Time | 1 | 1991 | 243 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 1991 | 758 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 6637 | 0.000 |
Why?
|